Company intelligence / Profile preview

uniQure

Amsterdam, Netherlandsuniqure.com ↗
Ownership
Public · QURE
Employees
~500
Development stage
Other
01

Overview

uniQure has achieved the world’s first approved gene therapy for hemophilia B. Its lead program in Huntington's disease has completed enrollment in multiple cohorts of a Phase I/II study and aligned with the FDA on an Accelerated Approval pathway. Other programs are advancing through early clinical development with positive interim safety data reported across several indications[7]. The company maintains strong cash reserves to fund operations into late 2027.

Therapeutic areas
HematologyRare DiseasesNeurology
Modalities
Adeno-associated virus (AAV)-based gene therapiesgene silencing via miQURE™ technology
Industry
Biotech
02

Drug pipeline

20 assets

alipogene tiparvovec

3

19 more assets in the full pipeline.

03

Partnerships

CSL Behring — commercialization partnership for hemophilia B program [4].Academic collaborations on drug discovery/preclinical research [3].
04

Financials

Market cap
$1.5B
Total revenue
$16.1M
Enterprise value
$851.3M

Beyond the preview

Go deeper on uniQure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on uniQure.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call